BioLineRx (BLRX) Long-Term Investments (2010 - 2018)
BioLineRx's (BLRX) quarterly Long-Term Investments came in at $1.0 million in Q1 2018, little changed quarter-over-quarter from $1.0 million in Q4 2017.
BioLineRx (BLRX) Long-Term Investments (2010 - 2018) Analysis & Trends
BioLineRx's Long-Term Investments history runs 4 years deep, the most recent figure standing at $1.0 million for Q1 2018.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $1.0 million in Q1 2018; TTM through Mar 2018 was $1.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $1.0 million, changed N/A from the prior year.
- Long-Term Investments steadied at $1.0 million in Q1 2018 per BLRX's latest filing, from $1.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $1.0 million in Q3 2017 and bottomed at $1.0 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 1.00 Mn |
| Dec 31, 2017 | 1.00 Mn |
| Sep 30, 2017 | 1.00 Mn |
| Jun 30, 2011 | 98.17 Mn |
| Dec 31, 2010 | 104.01 Mn |